H1 FY27: consolidated PAT up 38% YoY to ₹11.55 Cr, margins expand as revenue grows 30%
PAT +38% YoY · revenue +29.78% · margins expanding
₹211.63 Cr
+29.78% YoY
₹11.55 Cr
+38% YoY
5.44%
+0.3pp YoY
₹4.93
Mahamaya Lifesciences posted consolidated revenue of ₹211.63 Cr and PAT of ₹11.55 Cr for H1 FY27 (half year ended September 30, 2026), up 29.8% and 38.0% YoY from ₹163.06 Cr revenue and ₹8.37 Cr PAT in H1 FY26. The standalone print is near-identical (revenue ₹211.63 Cr, PAT ₹11.64 Cr, EPS ₹4.97 vs consolidated EPS ₹4.93), the small gap explained entirely by a still-dormant UAE subsidiary. PAT growing faster than revenue reflects genuine margin expansion, not a one-off — neither period carries an exceptional item, so adjusted growth equals the reported growth.
Q2 FY-2027 vs prior quarters
The expansion sits on operating leverage: consolidated net profit margin rose to 5.46% from 5.13% YoY, and EBITDA margin (PBT plus financial cost and depreciation, over revenue) widened to ~10.95% from ~10.03%, even as financial costs (₹6.19 Cr) and depreciation (₹1.43 Cr) both grew alongside a larger balance sheet — short-term borrowings rose to ₹111.69 Cr from ₹87.17 Cr at FY26-end as the company funds inventory and the new manufacturing plant.
The stock went into the print at ₹182.25, up 3.9% over the past month of trading.
What the summary numbers don't show
Consolidated subsidiary Mahamaya Lifesciences FZE (UAE) stays dormant — nil revenue, ₹8.80 Lakh net loss for H1, immaterial to group
No analyst consensus for this SME-platform stock surfaced in search, so vsStreet is unknown — there is no formal brokerage coverage to grade the print against. Management's only public marker is its own FY27 revenue guidance of ₹440-450 Cr (reported by Free Press Journal), contingent on monsoon, second-half demand and pesticide-registration timelines; H1's ₹211.63 Cr is ~47-48% of that range, a touch below the ~50% H1 share the company ran in FY26 (₹163.06 Cr of ₹328.87 Cr), so H2 needs to accelerate rather than merely repeat last year's seasonal split to hit the guide. The half closed with a governance change — on September 30, 2026 the board re-designated MD Krishnamurthy Ganesan to Chairman and appointed new directors, a leadership transition landing right at period-end rather than an operational driver of the print.
W1
FY27 revenue guide of ₹440-450 Cr implies H2 FY27 revenue of ~₹228-238 Cr, a 38-44% jump over H2 FY26's ₹165.8 Cr — watch if H2 accelerates past H1's 29.8% YoY pace
W2
Technical plant capex: ₹26.28 Cr of the ₹29.42 Cr IPO-proceeds allocation still unutilised as of Nov 3, 2026, against a Q4 FY27 commissioning guide
W3
Management has guided exports to 10-12% of FY27 revenue from ~1.7% currently — track the export mix in subsequent filings
Filing is a HALF-YEAR result (H1 FY27, half year ended 30-Sep-2026) — company is SME-listed and reports half-yearly not quarterly, so no standalone Q2 figure exists and QoQ is not computable; source in ₹ Lakhs, converted to Cr; consolidated includes near-dormant UAE subsidiary Mahamaya Lifesciences FZE (nil revenue, ₹8.80 Lakh net loss) which is the only standalone-vs-consolidated gap; no exceptional items either period, so adjusted YoY equals reported YoY.